Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Cash & Current Investments: 2021-2025

Historic Cash & Current Investments for Krystal Biotech (KRYS) over the last 5 years, with Sep 2025 value amounting to $731.1 million.

  • Krystal Biotech's Cash & Current Investments rose 24.26% to $731.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $2.6 billion, marking a year-over-year increase of 18.44%. This contributed to the annual value of $597.5 million for FY2024, which is 12.28% up from last year.
  • Latest data reveals that Krystal Biotech reported Cash & Current Investments of $731.1 million as of Q3 2025, which was up 7.20% from $682.0 million recorded in Q2 2025.
  • In the past 5 years, Krystal Biotech's Cash & Current Investments registered a high of $731.1 million during Q3 2025, and its lowest value of $343.1 million during Q3 2021.
  • In the last 3 years, Krystal Biotech's Cash & Current Investments had a median value of $562.1 million in 2023 and averaged $566.9 million.
  • In the last 5 years, Krystal Biotech's Cash & Current Investments declined by 19.38% in 2023 and then surged by 53.62% in 2024.
  • Over the past 5 years, Krystal Biotech's Cash & Current Investments (Quarterly) stood at $438.1 million in 2021, then dropped by 13.45% to $379.2 million in 2022, then spiked by 40.35% to $532.2 million in 2023, then increased by 12.28% to $597.5 million in 2024, then grew by 24.26% to $731.1 million in 2025.
  • Its last three reported values are $731.1 million in Q3 2025, $682.0 million for Q2 2025, and $616.8 million during Q1 2025.